Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HBB | P68871 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA7 | P43166 | 2/20 | 0.54 |
| ▸ | OGA | O60502 | 2/20 | 0.52 |
| ▸ | SLC27A1 | Q6PCB7 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3394204 | 0.89 | SMN1; SMN2 (0.64) | KDM4EALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL3392827 | 0.88 | CA1 (0.54) | KDM4EALDH1A1KMT2AMEN1CA1 | |
| SCHEMBL3393954 | 0.81 | CA1 (0.56) | ALDH1A1KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL3393276 | 0.78 | SLC27A1 (0.74) | KDM4EALDH1A1KMT2AMEN1CA1 | |
| SCHEMBL15943685 | 0.78 | SMN1; SMN2 (0.65) | KDM4EALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL3393148 | 0.78 | SLC27A1 (0.62) | KDM4EALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3390183 | 0.77 | MMP2 (0.65) | KDM4EALDH1A1KMT2ALMNACA1 | |
| SCHEMBL15943686 | 0.77 | SMN1; SMN2 (0.64) | KDM4EALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL3396176 | 0.77 | MEN1 (0.54) | KDM4EALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL7423903 | 0.76 | ALOX15 (0.60) | ALDH1A1KMT2AMEN1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-02-04 | — | — | US | claimed |
| EP-2024364-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2009-02-18 | — | — | EP | claimed |
| WO-2007137417-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-12-06 | — | — | WO | claimed |
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-02-04 | — | — | US | disclosed |
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-02-04 | — | — | US | disclosed |
| WO-2007137417-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, CACNA1I | KDM4E 3949/4885ALDH1A1 1881/4885KMT2A 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.